Novel GSK-3beta inhibitors from sequential virtual screening.

Area of Science:

• Medicinal Chemistry
• Computational Drug Discovery
• Biochemistry

Background:

• Glycogen synthase kinase-3 (GSK-3beta) is a significant therapeutic target for diseases including type-2 diabetes, Alzheimer's disease, cancer, and chronic inflammation.
• Novel drug design strategies are crucial for developing effective treatments for these conditions.

Purpose of the Study:

• To identify novel, biologically active compounds with potential as GSK-3beta inhibitors.
• To provide new insights for drug design targeting GSK-3beta.

Main Methods:

• Development of a 3D common feature pharmacophore model using HipHop in Catalyst software.
• Virtual screening of a commercial database using the pharmacophore model.
• Application of a Recursive Partitioning (RP) model for filtering active and inactive compounds.
• Sequential Virtual Screening Procedure (SQSP) combining pharmacophore and RP models.
• Selection of 56 hit compounds based on predicted docking modes in crystal structures.

Main Results:

• The SQSP successfully identified potential GSK-3beta inhibitors.
• Enzyme assays confirmed micromolar inhibitory activity for three of the selected hit compounds against human GSK-3beta.
• Detailed analysis of the binding modes of novel hit compounds within the GSK-3beta active site was performed.

Conclusions:

• The study successfully identified novel potent inhibitors of GSK-3beta.
• The identified compounds and their binding modes offer valuable information for future drug development targeting GSK-3beta.
• This research contributes to the ongoing effort to find new therapeutic agents for diseases associated with GSK-3beta dysregulation.